Compare SLN & AMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLN | AMTX |
|---|---|---|
| Founded | 1994 | 2005 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 318.4M | 150.1M |
| IPO Year | N/A | N/A |
| Metric | SLN | AMTX |
|---|---|---|
| Price | $6.37 | $1.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $39.67 | $17.00 |
| AVG Volume (30 Days) | 305.5K | ★ 831.2K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $25,830,000.00 | ★ $201,323,000.00 |
| Revenue This Year | N/A | $0.66 |
| Revenue Next Year | N/A | $118.86 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 40.39 | N/A |
| 52 Week Low | $1.97 | $1.22 |
| 52 Week High | $8.08 | $3.66 |
| Indicator | SLN | AMTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.63 | 34.34 |
| Support Level | $5.95 | $1.43 |
| Resistance Level | $6.60 | $1.60 |
| Average True Range (ATR) | 0.53 | 0.11 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 29.81 | 12.68 |
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Aemetis Inc is an renewable fuel and biochemicals company focused on the production of renewable fuels and chemicals through the acquisition, development and commercialization of technologies that replace traditional petroleum-based products through the conversion of first-generation ethanol and biodiesel plants into biorefineries. It owns and operates an approximately 65 million gallon per year ethanol production facility located in Keyes, California. In addition to low carbon renewable fuel ethanol, the Keyes Plant produces Wet Distillers Grains, Distillers Corn Oil, and Condensed Distillers Solubles, all of which are sold to local dairies and feedlots as animal feed. It operates in the reportable geographic segments of North America and India.